OBJECTIVE: Proton magnetic resonance spectroscopy ((1)H-MRS) studies of medicated patients with schizophrenia suggest high choline levels in the caudate nucleus. However, assessments of antipsychotic-naive patients are needed. METHOD: The authors studied 11 antipsychotic-naive schizophrenia patients and 11 normal comparison subjects with single-voxel (1)H-MRS of the left caudate nucleus. Concentrations of N-acetylaspartate, choline, and creatine were determined and corrected for the proportion of cerebrospinal fluid in the voxel. RESULTS: The patients with schizophrenia had significantly higher levels of choline than the comparison subjects, while the other two metabolites did not differ between groups. CONCLUSIONS: High caudate choline levels in schizophrenia are not secondary to antipsychotic treatment.
OBJECTIVE: Proton magnetic resonance spectroscopy ((1)H-MRS) studies of medicated patients with schizophrenia suggest high choline levels in the caudate nucleus. However, assessments of antipsychotic-naive patients are needed. METHOD: The authors studied 11 antipsychotic-naive schizophreniapatients and 11 normal comparison subjects with single-voxel (1)H-MRS of the left caudate nucleus. Concentrations of N-acetylaspartate, choline, and creatine were determined and corrected for the proportion of cerebrospinal fluid in the voxel. RESULTS: The patients with schizophrenia had significantly higher levels of choline than the comparison subjects, while the other two metabolites did not differ between groups. CONCLUSIONS: High caudate choline levels in schizophrenia are not secondary to antipsychotic treatment.
Authors: Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti Journal: Psychiatry Res Date: 2012-09-13 Impact factor: 3.222
Authors: Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Helgi Jung-Cook; Rodolfo Solís-Vivanco; Ariel Graff-Guerrero; Dikoma C Shungu Journal: Biol Psychiatry Date: 2017-10-10 Impact factor: 13.382
Authors: L Fredrik Jarskog; Zhengchao Dong; Alayar Kangarlu; Tiziano Colibazzi; Ragy R Girgis; Lawrence S Kegeles; Deanna M Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; Michael P Harms; Daniel C Javitt; Richard Se Keefe; Joseph P McEvoy; Robert P McMahon; Stephen R Marder; Bradley S Peterson; Jeffrey A Lieberman Journal: Neuropsychopharmacology Date: 2013-01-16 Impact factor: 7.853
Authors: Jeffrey A Stanley; Madhuri Vemulapalli; Jeffrey Nutche; Debra M Montrose; John A Sweeney; Jay W Pettegrew; Frank P MacMaster; Matcheri S Keshavan Journal: Schizophr Res Date: 2007-05-10 Impact factor: 4.939
Authors: Eric Plitman; Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Sofia Chavez; Gladys Gómez-Cruz; Pablo León-Ortiz; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2015-08-28 Impact factor: 9.306
Authors: Meredith A Reid; Nina V Kraguljac; Kathy B Avsar; David M White; Jan A den Hollander; Adrienne C Lahti Journal: Schizophr Res Date: 2013-05-21 Impact factor: 4.939
Authors: Nick C Patel; Kim M Cecil; Stephen M Strakowski; Caleb M Adler; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2008-12 Impact factor: 2.576